Curis

Yahoo Finance • 2 months ago

How The Curis (CRIS) Narrative Is Evolving As Assumptions Shift But The Target Stays

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Curis is back in focus as analysts reaffirm a $14.00 per share fai... Full story

Yahoo Finance • 5 months ago

After-Hours Gainers: Biotech Stocks Climb On Data Anticipation And Momentum Buying

(RTTNews) - U.S. after-hours trading on Wednesday saw a wave of gains across several small-cap and micro-cap biotech names, with a mix of catalyst-driven moves and sentiment-based rebounds. While a few companies advanced on upcoming clinic... Full story

Yahoo Finance • 10 months ago

Curis launches $7M direct and concurrent private placement

* Curis (NASDAQ:CRIS [https://seekingalpha.com/symbol/CRIS]) has entered into a definitive agreement for the purchase of 1.5M shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. * In a co... Full story

Yahoo Finance • 10 months ago

Curis raises $7 million through stock and warrant offerings

LEXINGTON, Mass. - Biotechnology company Curis, Inc. (NASDAQ:CRIS), currently valued at $22.49 million and showing weak financial health according to InvestingPro metrics, announced Wednesday it has secured approximately $7 million in fina... Full story

Yahoo Finance • 2 years ago

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combinati... Full story

Yahoo Finance • 2 years ago

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

LEXINGTON, Mass., Dec. 11, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, last night presented clinical dat... Full story

Yahoo Finance • 3 years ago

Curis to Present at Upcoming Healthcare Conferences in April

LEXINGTON, Mass., April 3, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief... Full story

Yahoo Finance • 3 years ago

Q4 2022 Curis Inc Earnings Call

Participants Diantha Duvall; CFO, Treasurer, Assistant Secretary, Principal Financial Officer & Principal Accounting Officer; Curis, Inc. James E. Dentzer; President, CEO & Director; Curis, Inc. Robert E. Martell; Head of Research & Dev... Full story

Yahoo Finance • 3 years ago

Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia

Curis to review results during conference call, featuring commentary by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET LEXINGTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS),... Full story

Yahoo Finance • 4 years ago

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass., Sept. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief... Full story

Yahoo Finance • 4 years ago

Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022

LEXINGTON, Mass., July 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second... Full story

Yahoo Finance • 4 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. (“Curis” or the “Company”) (NASDAQ: CRIS).   Such investors are advised to contact Robert S. Willoughby at  newactio... Full story

Yahoo Finance • 4 years ago

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., April 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2022, the independent C... Full story

Yahoo Finance • 4 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Curis, Inc. – CRIS

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. (“Curis” or the “Company”) (NASDAQ: CRIS). Such investors are advised to contact Robert S. Willoughby at newaction@p... Full story